To evaluate the association with the longitudinal changes, we estimated SPARE-Tau, average Braak score, meta-temporal ROI, and SPARE-AD cutoffs based on classifying CU Aβ- participants versus Aβ+ MCI and dementia participants. This evidence concerns the gene MAPT and Alzheimer disease.